GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (STU:DUL) » Definitions » E10

Alnylam Pharmaceuticals (STU:DUL) E10 : €-6.74 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.478. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-6.74 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -13.90% per year. During the past 5 years, the average E10 Growth Rate was -16.30% per year. During the past 10 years, the average E10 Growth Rate was -14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alnylam Pharmaceuticals was 30.10% per year. The lowest was -21.40% per year. And the median was -17.40% per year.

As of today (2024-06-09), Alnylam Pharmaceuticals's current stock price is €135.95. Alnylam Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €-6.74. Alnylam Pharmaceuticals's Shiller PE Ratio of today is .


Alnylam Pharmaceuticals E10 Historical Data

The historical data trend for Alnylam Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals E10 Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.29 -4.18 -5.17 -6.41 -6.71

Alnylam Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.35 -6.92 -6.77 -6.71 -6.74

Competitive Comparison of Alnylam Pharmaceuticals's E10

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Shiller PE Ratio falls into.



Alnylam Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alnylam Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.478/131.7762*131.7762
=-0.478

Current CPI (Mar. 2024) = 131.7762.

Alnylam Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.427 100.560 -0.560
201409 -0.450 100.428 -0.590
201412 -0.227 99.070 -0.302
201503 -0.573 99.621 -0.758
201506 -0.757 100.684 -0.991
201509 -0.811 100.392 -1.065
201512 -0.982 99.792 -1.297
201603 -1.087 100.470 -1.426
201606 -0.935 101.688 -1.212
201609 -1.078 101.861 -1.395
201612 -1.251 101.863 -1.618
201703 -1.169 102.862 -1.498
201706 -1.193 103.349 -1.521
201709 -1.124 104.136 -1.422
201712 -1.251 104.011 -1.585
201803 -1.144 105.290 -1.432
201806 -1.395 106.317 -1.729
201809 -2.083 106.507 -2.577
201812 -1.837 105.998 -2.284
201903 -1.531 107.251 -1.881
201906 -1.788 108.070 -2.180
201909 -1.743 108.329 -2.120
201912 -2.223 108.420 -2.702
202003 -1.466 108.902 -1.774
202006 -1.385 108.767 -1.678
202009 -1.851 109.815 -2.221
202012 -1.718 109.897 -2.060
202103 -1.436 111.754 -1.693
202106 -1.336 114.631 -1.536
202109 -1.462 115.734 -1.665
202112 -1.912 117.630 -2.142
202203 -1.816 121.301 -1.973
202206 -2.166 125.017 -2.283
202209 -3.353 125.227 -3.528
202212 -1.586 125.222 -1.669
202303 -1.308 127.348 -1.353
202306 -2.040 128.729 -2.088
202309 1.078 129.860 1.094
202312 -1.009 129.419 -1.027
202403 -0.478 131.776 -0.478

Add all the adjusted EPS together and divide 10 will get our e10.


Alnylam Pharmaceuticals  (STU:DUL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alnylam Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (STU:DUL) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (STU:DUL) Headlines

No Headlines